Press coverage about GenVec (NASDAQ:GNVC) has trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GenVec earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.1142306094917 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of GenVec (GNVC) traded up 0.000% during midday trading on Thursday, hitting $7.193. GenVec has a 1-year low of $0.27 and a 1-year high of $10.44. The company’s 50-day moving average price is $6.74 and its 200-day moving average price is $5.80.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at

GenVec Company Profile

GenVec, Inc (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria.

Insider Buying and Selling by Quarter for GenVec (NASDAQ:GNVC)

Receive News & Ratings for GenVec Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec Inc and related companies with's FREE daily email newsletter.